SLC17A9 expression levels in a pan‑cancer panel and validation of the role of SLC17A9 as a novel prognostic biomarker for osteosarcoma

Li,Junqing; Wu,Feiran; Su,Li; Zhu,Huimin; Yao,Jie; Zhang,Meng

doi:10.3892/ol.2023.13969

SLC17A9 expression levels in a pan‑cancer panel and validation of the role of SLC17A9 as a novel prognostic biomarker for osteosarcoma

Authors:
- Junqing Li
- Feiran Wu
- Li Su
- Huimin Zhu
- Jie Yao
- Meng Zhang
View Affiliations

Affiliations: Minimally Invasive Spinal Surgery Center, Luoyang Orthopedic‑Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital), Zhengzhou, Henan 450018, P.R. China, Department of Orthopedics, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan 450003, P.R. China
Published online on: July 20, 2023 https://doi.org/10.3892/ol.2023.13969
Article Number: 383
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated the involvement of the solute carrier family 17 member 9 (SLC17A9) in certain types of cancer; however, the precise role of SLC17A9 is not well defined. In the present study, a comprehensive analysis was performed to determine the involvement of SLC17A9 in a pan‑cancer panel. First, data on SLC17A9 expression levels from publicly available databases were obtained to determine SLC17A9 expression profiles in various types of cancer. Next, the involvement of SLC17A9 in the prognosis of patients, stemness indices and the immune microenvironment was examined in 34 types of cancer. Furthermore, CCK‑8 and colony‑formation assays were performed to determine the effect of SLC17A9 on osteosarcoma (OSS) cells. In a pan‑cancer panel, a difference in SLC17A9 expression levels was observed in the tumor tissues as compared with healthy tissues. Furthermore, survival analysis revealed a significant association between SLC17A9 expression levels and the prognosis of patients with various cancer types, including adrenocortical carcinoma, kidney renal clear cell carcinoma, glioblastoma, kidney renal papillary cell carcinoma, low grade glioma, liver hepatocellular carcinoma, mesothelioma, lung adenocarcinoma, skin cutaneous melanoma, uveal melanoma, stomach adenocarcinoma and OSS. The results of the present study revealed correlations between stemness indices, tumor immunity and SLC17A9 expression levels. Furthermore, univariate and multivariate Cox regression analyses indicated that SLC17A9 may be utilized as an independent risk factor for overall survival of patients with OSS. In vitro experiments demonstrated that SLC17A9 promotes the proliferation and viability of OSS cells. Taken together, the results of the present study suggest an association between SLC17A9 and the prognosis of patients as well as tumor immunity in various cancer types. SLC17A9 may serve as a novel prognostic biomarker and target for improving the prognosis of patients with OSS.

View Figures

View References

1	Cao Q, Zhao K, Zhong XZ, Zou Y, Yu H, Huang P, Xu TL and Dong XP: SLC17A9 protein functions as a lysosomal ATP transporter and regulates cell viability. J Biol Chem. 289:23189–23199. 2014. View Article : Google Scholar : PubMed/NCBI
2	Huang P, Cao Q, Xu M and Dong XP: Lysosomal ATP Transporter SLC17A9 controls cell viability via regulating cathepsin D. Cells. 11:8872022. View Article : Google Scholar : PubMed/NCBI
3	Yang L, Chen Z, Xiong W, Ren H, Zhai E, Xu K, Yang H, Zhang Z, Ding L, He Y, et al: High expression of SLC17A9 correlates with poor prognosis in colorectal cancer. Hum Pathol. 84:62–70. 2019. View Article : Google Scholar : PubMed/NCBI
4	Li J, Su T, Yang L, Deng L, Zhang C and He Y: High SLC17A9 expression correlates with poor survival in gastric carcinoma. Future Oncol. 15:4155–4166. 2019. View Article : Google Scholar : PubMed/NCBI
5	Sun M, Qiu J, Zhai H, Wang Y, Ma P, Li M and Chen B: Prognostic implications of novel gene signatures in gastric cancer microenvironment. Med Sci Monit. 26:e9246042020. View Article : Google Scholar : PubMed/NCBI
6	Kui XY, Gao Y, Liu XS, Zeng J, Yang JW, Zhou LM, Liu XY, Zhang Y, Zhang YH and Pei ZJ: Comprehensive analysis of SLC17A9 and its prognostic value in hepatocellular carcinoma. Front Oncol. 12:8098472022. View Article : Google Scholar : PubMed/NCBI
7	Mi YY, Sun CY, Zhang LF, Wang J, Shao HB, Qin F, Xia GW and Zhu LJ: Long Non-coding RNAs LINC01679 as a competitive endogenous RNAs inhibits the development and progression of prostate cancer via regulating the miR-3150a-3p/SLC17A9 axis. Front Cell Dev Biol. 9:7378122021. View Article : Google Scholar : PubMed/NCBI
8	Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al: Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
9	Blum A, Wang P and Zenklusen JC: SnapShot: TCGA-Analyzed tumors. Cell. 173:5302018. View Article : Google Scholar : PubMed/NCBI
10	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45((W1)): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lánczky A and Győrffy B: Web-Based survival analysis tool tailored for medical research (KMplot): Development and implementation. J Med Internet Res. 23:e276332021. View Article : Google Scholar : PubMed/NCBI
12	Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, et al: Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 173:338–354.e15. 2018. View Article : Google Scholar : PubMed/NCBI
13	Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:26122013. View Article : Google Scholar : PubMed/NCBI
14	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
15	Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J and Pommier Y: CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72:3499–3511. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hänzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
18	Li J, Su L, Xiao X, Wu F, Du G, Guo X, Kong F, Yao J and Zhu H: Development and validation of novel prognostic models for immune-related genes in osteosarcoma. Front Mol Biosci. 9:8288862022. View Article : Google Scholar : PubMed/NCBI
19	Wu J, Yang Y and Song J: Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance. Oncol Lett. 20:1822020. View Article : Google Scholar : PubMed/NCBI
20	Hao X, Luo H, Krawczyk M, Wei W, Wang W, Wang J, Flagg K, Hou J, Zhang H, Yi S, et al: DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci USA. 114:7414–7419. 2017. View Article : Google Scholar : PubMed/NCBI
21	Meng M, Lan T, Tian D, Qin Z, Li Y, Li J and Cao H: Integrative bioinformatics analysis demonstrates the prognostic value of chromatin accessibility biomarkers in clear cell renal cell carcinoma. Front Oncol. 11:8143962021. View Article : Google Scholar : PubMed/NCBI
22	Xiao Y and Yu D: Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 221:1077532021. View Article : Google Scholar : PubMed/NCBI
23	Roma-Rodrigues C, Mendes R, Baptista PV and Fernandes AR: Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 20:8402019. View Article : Google Scholar : PubMed/NCBI
24	Crotty S: T follicular helper cell biology: A decade of discovery and diseases. Immunity. 50:1132–1148. 2019. View Article : Google Scholar : PubMed/NCBI
25	Li C, Jiang P, Wei S, Xu X and Wang J: Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 19:1162020. View Article : Google Scholar : PubMed/NCBI